Pharma Finland

Central nervous system, CNS

Research on central nervous system (CNS) diseases in Finland has resulted in an especially strong level of expertise in Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Basic and clinical research on CNS is performed in particular in Helsinki, Turku, Kuopio and Tampere. Examples of the research done there include:

  • Research on nerve growth factors at the University of Helsinki and Hermo Pharma Ltd
  • Research on α-receptors in Alzheimer’s disease at Orion Corporation
  • Multiple sclerosis (MS) disease is a special focus area at the University of Tampere
  • Turku PET Centre has gained world-class expertise and know-how in PET imaging used in AD and PD research

One example of Finnish commercial success in the treatment of Parkinson’s disease is entacapone, a globally marketed drug developed by Orion Corporation. Other examples of Finnish commercial products are nalmefene, developed by Biotie Therapies Corporation to treat alcohol dependence (cooperation with Lundbeck A/S), and Nexstim Oy’s Navigated Brain Stimulation imaging devices.

Today, research activities in the CNS field are focused on, for example, nerve growth factors, α-receptor research, neural plasticity research, epidemiological risk factor research and stem cell research.

The following links include some examples of organizations with CNS disease expertise in Finland:

Biotech/pharma companies

Biotie Therapies Corporation
Hermo Pharma Ltd
Medeia Therapeutics Ltd
Orion Corporation

Academic research

BioCenter Finland
FIMM – Molecular Medicine
TCDM – Disease Models
Turku PET Centre


Charles River Finland 
Crown CRO Oy
CRST – Clinical Research Services Turku 
Medfiles Ltd 
Neurotar Oy
Systems Biology Worldwide Ltd


Elekta Oy
GE Healthcare Finland Oy 
MAP Medical Technologies Oy
Mediracer Oy 
Nexstim Oy

ICT solutions

Atrotech Ltd 
Mega Electronics Ltd